Dyne details pivotal plans for myotonic dystrophy RNA drug, though data blip worries some investors

Dyne Therapeutics touted an early-stage study of its RNA treatment for myotonic dystrophy type 1 and has selected the dose it plans to move forward into pivotal studies. However, the company’s shares fell Friday morning ...